cota-logo-wht-rgb
Contact Us
cota-logo-wht-rgb

COTA expands clinicogenomics offering with Genomic Testing Cooperative partnership.

Click to read more

Advance with clarity

When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.

Our Approach

COTA leverages our proprietary abstraction technology and oncology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation.

We form flexible and collaborative partnerships with life science companies to shape the future of real-world evidence.

Our Value

#6846 - COTA Healthcare homepage redesign - inform

Inform

Market of current oncologics and decisions to drive future therapeutic areas.

Read Customer Case Study:

Download Now
#6846 - COTA Healthcare homepage redesign - accelerate

Accelerate

Drug development and build real-world comparator arms.

Read Customer Case Study:

Download Now
#6846 - COTA Healthcare homepage redesign - inspire

Inspire

New ways of thinking about how trials are designed.

Read Customer Case Study:

Download Now

Our Difference

Data Source

  • Records sourced from tertiary referral centers capture complex and advanced cancers with rigorous EMR documentation and genomic profiling capabilities.

Abstraction

  • Technology enabled human abstraction allows for nuances in unstructured data to be captured manually by medical professionals.

Flexibility

  • Solution-oriented agility enables rapid assessment and implementation of augmentation requests.

Curation Depth

  • COTA’s standard-level dataset goes deeper than traditional sources, capturing the clinical information that is most valuable to life sciences.

Our Products

STANDARD: Data elements defined by our medical team and key industry opinion leaders. Includes demographics, diagnostics, performance status, molecular markers, labs, treatments, and outcomes.

*Complexity based on ability to define, curate, and deliver; can include additional biomarkers, labs, imaging, pathology, and more.

Getting Focused

COTA captures clinical data from EHR from multiple provider sources across the United States, including both academic and community cancer programs. We also use non-EHR sources such as publicly available and proprietary databases, to generate a rich and precise dataset for use by life sciences companies.

COTA collects all clinically-relevant data points to create a rich, in-depth longitudinal cancer patient journey from our healthcare providers’ EHR. Data elements captured may vary per cancer type, but generally, our data contains (but is not limited to) detailed demographic, pathologic, genomic, treatment, and outcomes data.

Life sciences companies have used our data to support HEOR, commercial assessments, and clinical development, including supplementing clinical trial data with RWD in the form of external comparator controls. We are open to discussing any other opportunities, as well as your data needs and how COTA can generate value for your organization.

We work with life science companies interested in using oncology RWD to accelerate drug development and bring clarity to cancer. We work with the top global pharmaceutical companies, though our partners range from multinational pharma to emerging biotechs.

Our collaborative and flexible approach enables us to succeed with emerging biopharma partners. We work alongside EBPs to provide analytical, medical, and strategic support to validate use of COTA data towards EBP goals.

Latest Resources

The two companies are joining forces to integrate COTA’s deep clinical oncology real-world data with GTC’s comprehensive genomics testing data.

In Move to Power Precision Oncology for Patients, COTA and Genomic Testing Cooperative Form New Data Partnership

The two companies are joining forces to integrate COTA’s deep clinical oncology real-world data with GTC’s comprehensive genomics testing data.
read more

COTA, Inc. Forms Strategic Real-World Data Research Partnership with the Clinical Research Data Sharing Alliance

COTA, Inc. is now a proud member of the Clinical Research Data Sharing Alliance (CRDSA). This cross-industry alliance is dedicated to accelerating the discovery and delivery of life-saving therapies through the use of high-quality clinical trials and real-world data.
read more

Using Fit-for-Purpose Data to Improve Patient Outcomes With Seshamalini Srinivasan, Karla Feghali, Mandy Kelly, Laura Fernandes

In the world of clinical trials, having a well-defined research question is key. And that’s where fit-for-purpose data sets come in. But what are the factors for defining research questions? In this episode of the Real World Talk podcast, we get to hear from Seshamalini Srinivasan, Karla Feghali, Mandy Kelly, and Laura Fernandes. They talk about the criteria for defining research questions, the importance of fit-for-purpose data, and the other factors to consider in real-world data sources.
listen now

Interested in learning more about how we can transform cancer care together?

LEARN MORE

Bringing clarity to cancer

We are working to ensure that everyone touched by cancer has a clear path to the right care.

Privacy Policy

Terms of Use

CCPA Privacy Notice

Subscribe for Updates

Receive our latest news and research from thought leaders in the RWD industry
  • This field is for validation purposes and should be left unchanged.